30 September 2026, 14:00 pm BST | Free online event
Therapeutic antibodies are becoming more sophisticated. But which scientific challenges are we actually solving – and which remain stubbornly difficult?
As therapeutic antibodies become increasingly complex, success depends on understanding far more than whether an antibody binds its target.
Researchers need to understand how antibodies interact with receptors and antigens, how structure influences function, how candidates can be engineered for therapeutic performance and how new formats can translate into effective treatments.
All of this will be explored in our expert led webinar, which will bring together an expert panel of researchers working across structural immunology, molecular immunology, cancer therapeutics, antibody engineering and systems immunology.
Access the free webinar by registering for a membership or logging into your account.
A translational B cell and cancer immunologist, Professor Karagiannis works on antibody and antibody–drug conjugate engineering and novel cancer immunotherapies. She pioneered the design and clinical translation of IgE-based cancer therapeutics and founded Epsilogen Ltd.
Professor Davis investigates how lymphocyte receptors, including immune checkpoints, are triggered. His research combines structural and functional approaches to understand cell-surface biology and immune regulation.
Dr Julien’s multidisciplinary research focuses on the molecular characteristics of antibodies and their interactions with viral, bacterial, parasitic and cell-surface antigens, using structural approaches to understand antibody recognition.
Professor Pors researches cancer pharmacology, chemical biology and tumour-selective therapies, including anticancer agents, prodrugs and approaches to overcoming drug resistance.
Professor Lippert investigates how immune cells perceive and respond to their physical environment, with research spanning T-cell mechanosensing, immune-cell activation and autoantibodies in autoimmune disease.
What will you learn?
- How researchers are improving our ability to design and develop antibodies with the properties needed for therapeutic applications.
- What structural and molecular insights can tell us about antibody recognition, receptor interactions and therapeutic performance.
- Where the fundamental gaps are in our understanding and how they are still limiting antibody discovery and development.
- How approaches such as antibody–drug conjugates are expanding the potential of antibody-based therapeutics.
- What scientific advances could have the greatest impact on the development of the next generation of antibody therapeutics.
Who should attend?
This webinar is relevant to scientists and research professionals working in antibody discovery, engineering, structural biology, immunology and therapeutic development.
It will also be valuable for professionals involved in drug discovery, biologics development and the research and development of antibody-based therapeutics, including antibody–drug conjugates.
Join the conversation
Whether you work in antibody discovery, engineering, structural biology or therapeutic development, this live expert discussion will give you a clearer view of the scientific progress shaping the field – and the questions researchers still need to answer.
Access the free webinar by registering for a membership or logging into your account.
Is the panel discussion free?
Yes – there is no charge to watch the panel discussion, either live or on-demand.
When will the panel discussion take place?
The webinar will be taking place on September 30th 2026
Can I watch it later?
The panel discussion will become available to watch on-demand shortly after the live webinar takes place.
What are the benefits of attending live?
You’ll be able to ask the speakers your questions, which will be answered live in the Q&A towards the end of the session.
How long will the panel discussion be?
This panel discussion will last up to an hour.
What do I need to watch this panel discussion?
All you need is a computer with an internet connection. We recommend using headphones if possible if you’re in an office environment.
